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Abstract. Erythropoeitin is the most important factor in
the regulation of erythropoeisis. This study aimed to eval-
uate the eﬃcacy of rhuESF for patients undergoing plastic
surgical procedures during which notable blood loss is ex-
pected (reduction mammoplasty in cases of macromastia
and abdominoplasty obese patients) to improve the full
blood count and reduce the need for transfusion. The levels
of hemoglobin were signiﬁcantly greater for patients pre-
treated with erythropoeitin and iron than for the control
group.
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Erythropoeitin (erythropoiesis-stimulating factor
[ESF]) is a complex glycoprotein considered to be the
most important factor in the regulation of erythro-
poeisis. The kidney has an important role in the
production of erythropoeitin in the form of an acti-
vator erythrogenin that transforms an inactive cir-
culating protein into active erythropoeitin. This acts
on stem cells, stimulating their diﬀerentiation into
erythroid cells [7]. The clinical uses of erythropoeitin
in the form of recombinant human erythropoeitin
(rhuESF) are limited to anemia caused by renal fail-
ure because the lowest levels of erythropoeitin are
found in the kidney, and to bone marrow transplants,
in which it is able to stimulate the resumption of
erythropeisis. Scientiﬁc evidence does not exist to
demonstrate the eﬃcacy of exogenous erythropoeitin
in the therapeutic control of anemia resulting from
protein deﬁciency, pregnancy, chronic infective ill-
nesses, neoplasia, or surgery [5,6]. This study aimed
to evaluate the eﬃcacy of rhuESF in the treatment of
patients undergoing plastic surgical procedures in
which notable blood loss is expected to improve the
full blood count and reduce the need for transfusion.
Materials and Methods
The prechosen interventions in our study are among
those involving the most blood loss in plastic surgery:
reduction mammoplasty in cases of macromastia and
abdominoplasty for in obese patients. For these, an
intraoperative blood loss of approximately 400 to
600 ml is expected. This is managed sometimes with
the transfusion of homologous blood, and in rare
cases, autologous blood [1,3,4,9,11,12,14,15].
The study involved 30 patients (13 men and 17
women) between the ages or 24 and 62 years (median
age, 43 ± 5 years). These patients, weighing 53 to
94 kg, (median, 73.5 ± 5 kg), represented American
Society of Anesthesiology (ASA) classes 1 and 2.
The patients were subdivided into two groups,
group A and group B, on the basis of their waiting list
position. Group A contained 15 patients. Eight of
these patients underwent abdominoplasty, and seven
were treated with reduction mammoplasty. Because
their hemoglobin levels were between 10.8 and 13.0 g/
dl (median 11.8 g/dl), they received, 500 mg/24 h of
iron orally for 14 days before the intervention, and a
single dose of rhuESF 40,000 units on the 14th and
7th days before surgery.
Group B (the control group) contained 15 patients.
Eight of these patients underwent abdominoplasty,
and seven were treated with reduction mammoplasty.
Because their preoperative hemoglobin levels ranged
from 11.0 to 13.8 g/dl (median, 12.4 g/dl), they were
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given 500 mg/24 h of iron orally for the 14 days be-
fore their intervention.
The patients excluded from the study included
those aﬀected by hematologic disease, serious
hypertension, unstable angina pectoris, congestive
cardiac failure, or cerebrovascular events during the
preceding 12 months.
All the patients underwent a blood test to deter-
mine full blood count, reticulocyte, ferritin, trans-
ferrin, and iron levels. The same tests were performed
during the immediate preoperative period, then on
days 1, 3, 7, and 10 postoperatively.
During the intervention, all the patients underwent
continuous monitoring of electrocardiogram in lead
2, frequency, systolic blood pressure, diastolic blood
pressure, median blood pressure, and hourly urine
output.
Statistical analysis was conducted using the Stu-
dent’s t-test, and p values less than 0.05 were con-
sidered signiﬁcant.
Results
Among the haematologic parameters examined,
transferrin, iron, and ferritin levels did not show
signiﬁcant variation between the two groups. The
levels of hemoglobin, however, were markedly dif-
ferent.
The patients in group A demonstrated a consider-
able increase in hemoglobin values preoperatively,
from 11.9 g/dl to 14.9 g/dl, and a smaller decrease
postoperatively. The average amount of blood
transfused was 0 units in group A and 1.6 in group B.
There were no side eﬀects particularly attributable to
the administration of rhuESF, and furthermore, the
postoperative general condition of the patients in
group A was better (Table 1) [2,4,12].
Discussion
Blood transfusion, traditionally considered to be a
therapeutically eﬀective and essential support for
modern medicosurgical practice is increasingly re-
garded as aprocedure toavoid.Despite the adoptionof
severemeasures in the selectionofblooddonorsand the
introduction of ever more sensitive tests to detect sub-
jects carrying transmittable infective agents, transfu-
sion therapy absolutelywithout risks does not exist and
probably will not exist in the future. The use of
homologous blood can be reduced, not only with the
adoptionofautotransfusionmethods,butalso through
the use of drugs that can increase the volume of ery-
throcytes or reduce the intraoperative blood loss. In
agreement with the data in the literature, our study
conﬁrmed that among the drugs currently available,
rhuESF is particularly eﬀective in limiting the
requirement of homologous blood transfusions in se-
lected patients among candidates for surgical inter-
ventions inwhich a signiﬁcant loss of blood is expected.
Studies have shown rhuESF to be eﬀective for ery-
thropoeisis stimulation, for expansion of the circulat-
ing erythrocytic mass, for increasing the volume of
autologous blood that the patient is able to store to
reduce theuseof allogenicblood,and for improving the
outcome experienced by the patients themselves [8,13].
The data obtained in our study, although pre-
liminary, leads us to believe that the use of rhuESF
preoperatively is safe and eﬀective for selected plastic
surgical interventions: reduction mammoplasty and
abdominoplasty. Furthermore, the cost for 40,000
units of rhuESF is about 370 euros, as compared with
500 euros for an auto trasfusion.
Notably, this study found that the substantial in-
crease in hemoglobin values during the preoperative
phase allowed optimal management of postoperative
anemia, reducing the likelihood of transfusions and
increasing the levels of hemoglobin and hematocrit
Table 1. Numeric and graphic representation of hemoglobin concentrations in the immediate preoperative period and in the
days after surgical interventions
Hb Pre Epo Hb preop (g.dl) Day 1 postop Day3 postop Day 7 postop Day 10 postop
Group A 11.8 ± 0.2 14.9 ± 0.5 11.7 ± 0.4 11.1 ± 0.2 10.7 ± 0.5 10.9 ± 0.3
Group B 12.4 ± 0.2 12.6 ± 0.2 9.6 ± 0.3 8.9 ± 0.4 8.4 ± 0.2 8.6 ± 0.64
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without increasing the thrombotic risk. Therefore, the
reported treatment represents a useful addition to the
current techniques for autotransfusion and saving of
blood and may be capable of extension to other
reconstructive procedures involving notable blood
loss.
Summary
32 patients underwent plastic surgical procedures ab-
dominoplasty and reductionmammoplasty forwhich a
signiﬁcant blood loss was expected. To evaluate the
eﬀectiveness of rHuESF in improving full blood count
and reducing the need for transfusions, expected. The
patients were subdivided into two groups (group A,
underwent treatmentwith rhuESFand iron, and group
B served as the control group). Both groups underwent
periodic blood tests in the immediate postoperative
period. Among the haematologic parameters exam-
ined, transferrin, iron, and ferritin levels did not show
signiﬁcant variationbetween the twogroups.However,
the levels of hemoglobin were signiﬁcantly higher
among the patients pretreated with erythropoeitin and
iron than in the control group. Therefore, the use of
rHuESF preoperatively is particularly safe and eﬀec-
tive for plastic surgical procedures during which sig-
niﬁcant loss of blood is expected, allowing optimal
management of postoperative anemia, reducing the
likelihood of transfusions, and increasing the levels of
hemoglobin and hematocrit without increasing the
thrombotic risk.
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